Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

European phase II study of 20 patients reported in Annals of Oncology

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication, by two European institutions, of results of a limited phase II study of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by administration of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60 years of age or older) with previously untreated diffuse large B-cell lymphoma (DLBCL). In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks later. The study, which had an overall response rate (ORR) of 100 percent, including a 95 percent complete remission (CR) rate, indicated the efficacy, tolerability, and feasibility of this regimen for these patients. Results of the study were reported in the online edition of February 2008 Annals of Oncology. CTI acquired the U.S. rights to Zevalin in December, 2007.

"Although a small phase II experience, these results in elderly lymphoma patients treated with Zevalin following CHOP without rituximab demonstrate high rates of complete remissions and overall survival and are consistent with the potential to use Zevalin as consolidation therapy in aggressive lymphoma," noted Jack W. Singer, M.D., Chief Medical Officer of CTI. "We continue to be impressed with the high rate of conversion of partial to complete remissions following Zevalin consolidation irrespective of whether or not rituximab therapy is utilized. This publication demonstrates this in elderly patients with DLBCL while similar data in indolent lymphomas were reported at ASH 2007 fr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... oxide ceramics have potential uses as ferroelectrics, fast ... nuclear waste, generating a great deal of scientific ... these blended materials. , "The interfaces separating the ... radiation properties of the material as a whole," ... researcher on the project. "It is in the ...
(Date:9/23/2014)... 2014 Erlab , the expert ... 1968 and Burdinola, supplier of laboratory furniture solutions, announce ... fume hood. , By integrating Erlab’s ... will now offer an innovative solution utilizing the patented ... chemicals, best-in-class detection technology, and communication for security and ...
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 For the ... Inc. 500|5000 list of the fastest-growing companies. , ... been acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony ... 5000 list by posting a three-year growth rate of 61 ... in that time by more than 40 percent. , Pappas ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
Breaking Biology Technology:Los Alamos researchers uncover properties in nanocomposite oxide ceramics for reactor fuel 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2
... , BOSTON, Sept. 15 The Center for ... host their October Summit taking place at the Marriott Tyson,s Corner, ... compliance space from leading pharmaceutical and biotech companies assemble to discuss ... industry. , , Featuring: , , ...
... NEW YORK, Sept. 15 A study exploring the ... mixtures could not proceed to completion and was now ... company engaged in the research and development of ozone-based ... its scope, was to be performed in Egypt, recruiting ...
... 15 Pieris AG,today announced that they have entered ... AGN ) that combines Pieris, proprietary Anticalin,technology with Allergan,s ... goal of developing agents for the treatment of serious,ocular ... of the collaboration Pieris will work with Allergan to,optimize ...
Cached Biology Technology:CBI Hosts Life Sciences Summit on International Trade Compliance 2Second U.S.-Egypt Collaborative Clinical Study Blocked by New York State Department of Health (NYSDOH), This Time on Complications of Diabetes 2Second U.S.-Egypt Collaborative Clinical Study Blocked by New York State Department of Health (NYSDOH), This Time on Complications of Diabetes 3Pieris AG Enters into Anticalin Collaboration With Allergan, Inc. 2
(Date:9/23/2014)... of removing infant chimpanzees from their mothers are well ... this type of early life experience. In a year-long ... and concluded that those who were removed from their ... pets or performers are likely to show behavioral and ... published today in the open-access journal PeerJ , ...
(Date:9/22/2014)... Chicago have shown that after a long stay in ... pathogenic microbe species remain behind in patients, intestines. The ... can become deadly when provoked by conditions that mimic ... published in mBio , the online open-access journal ... better monitoring and treatment of ICU patients who can ...
(Date:9/22/2014)... native species have vanished from tropical islands because ... have discovered how fossils can be used to ... in organic materials found in fossil bones, which ... to a new study available online and in ... Herpetology . Pre-human island ecosystems provide vital clues ...
Breaking Biology News(10 mins):Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Answer to restoring lost island biodiversity found in fossils 2
... Those ferocious Hollywood meat-eating dinosaurs you,re used to seeing ... side: the males might even have been sort of ... a Texas A&M University researcher. Jason Moore, a post-doctoral ... team members from Montana State University, Florida State University ...
... Henry Samueli School of Engineering and Applied Science have ... Escherichia coli , a bacterium often associated with ... the creation of biofuels. "Previously, ... carbon atoms," said James Liao, UCLA professor of chemical ...
... OAK RIDGE, Tenn. Dec. 18, 2008 -- In 2009, ... processor hours available on Jaguar, its Cray XT supercomputer, ... Impact on Theory and Experiment, or INCITE, program. ... in critical areas such as climate studies, energy assurance, ...
Cached Biology News:Male dinosaurs may have been prehistoric babysitters, study shows 2Researchers push nature beyond its limits to create higher-density biofuels 22009 DOE INCITE projects allocated at ORNL 22009 DOE INCITE projects allocated at ORNL 3
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Biology Products: